Last reviewed · How we verify
NCT02039986
Ivacaftor (Kalydeco) and Insulin in Cystic Fibrosis (CF)
trial in Cystic Fibrosis Related Diabetes in 13 participants. Completed in 11 October 2016.
11 October 2016
Quick facts
| Lead sponsor | Children's Hospital of Philadelphia |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 13 |
| Start date | 6 January 2014 |
| Primary completion | 11 October 2016 |
| Estimated completion | 11 October 2016 |
| Sites | 1 location across United States |
Conditions studied
- Cystic Fibrosis Related Diabetes — all drugs for Cystic Fibrosis Related Diabetes →
- Cystic Fibrosis — all drugs for Cystic Fibrosis →
Sponsor
Children's Hospital of Philadelphia
Who can join
6 and older, any sex, with Cystic Fibrosis Related Diabetes or Cystic Fibrosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is aimed at better understanding the impact of ivacaftor upon insulin and incretin secretion and glucose tolerance in patients with Cystic Fibrosis with a glycine (G551D) mutation. Investigators hypothesize that treatment with ivacaftor improves insulin secretion in individuals with CF.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Glucose >200 mg/dL during Continuous Glucose Monitoring Identifies Adult Patients at Risk for Development of Cystic Fibrosis Related Diabetes.
Taylor-Cousar JL, Janssen JS, Wilson A, Clair CG, et al · · 2016 · cited 29× · PMID 27999822 · DOI 10.1155/2016/1527932 -
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Skilton M, Krishan A, Patel S, Sinha IP, et al · · 2019 · cited 18× · PMID 30616300 · DOI 10.1002/14651858.cd009841.pub3 -
Cystic Fibrosis Treatment: A Paradigm for New Pediatric Medicines, Globalization of Drug Development and the Role of the European Medicines Agency.
Rose K, Spigarelli MG. · · 2015 · cited 2× · PMID 27417354 · DOI 10.3390/children2010108
Verify or expand the search:
- PubMed search for NCT02039986
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Children's Hospital of Philadelphia trials
Trials by the same sponsor.
- NCT07023380 — EoE Food Test Pilot Study · NA · not yet recruiting
- NCT06693752 — CEUS Evaluation of Hydrocephalus in Neonates and Infants · Phase 2 · recruiting
- NCT07425691 — SPACE for Youth With Chronic Pain · recruiting
- NCT07444528 — Upper Airway Ultrasound to Predict Difficult Laryngoscopy in Neonates and Infants · enrolling by invitation
- NCT07321327 — Implementation Strategies for Caregiver and Teacher Use of Behavioral Interventions: Aim 2 · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02039986 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Children's Hospital of Philadelphia
- Last refreshed: 14 December 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02039986.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing